Iovance Biotherapeutics, Inc. filed a Form 8-K on October 29, 2026, announcing updated clinical results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial alongside a biomarker-enriched precision tumor infiltrating lymphocyte strategy for lifileucel in previously treated non-squamous metastatic non-small-cell lung cancer.

Key Highlights

  • Trial update: Iovance disclosed updated results from Cohorts 1 and 2 of the Phase 2 IOV-LUN-202 trial, according to the filing.
  • Therapy focus: The results cover lifileucel, a tumor infiltrating lymphocyte therapy, in previously treated non-squamous metastatic non-small-cell lung cancer.
  • Precision strategy: The company announced a biomarker-enriched precision tumor infiltrating lymphocyte strategy alongside the clinical data, the filing stated.
  • Announcement vehicle: The disclosure was made via a press release dated October 29, 2026, attached as Exhibit 99.1 and incorporated by reference.
  • Signatory: The filing was signed by Frederick G. Vogt, Ph.D., J.D., in his capacity as Interim CEO and President, and General Counsel.

Iovance Biotherapeutics Discloses Phase 2 IOV-LUN-202 Cohort Data for Lifileucel

According to the filing, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) submitted a current report under Item 8.01 (Other Events) to disclose updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 clinical trial. The trial evaluates lifileucel, the company's tumor infiltrating lymphocyte therapy, in patients with previously treated non-squamous metastatic non-small-cell lung cancer. The company also disclosed what it described as a biomarker-enriched precision tumor infiltrating lymphocyte strategy in connection with those results.

The filing does not itself contain the clinical data; instead, it incorporates by reference a press release dated October 29, 2026, attached as Exhibit 99.1. No specific efficacy figures, response rates, or patient counts are reproduced within the body of the 8-K. The filing was reported under Item 8.01 and does not invoke any of the Securities Act or Exchange Act pre-commencement or soliciting-material provisions checked on the cover page.

The report was signed on October 29, 2026, by Frederick G. Vogt, Ph.D., J.D., identified in the filing as Interim CEO and President, and General Counsel of Iovance Biotherapeutics, Inc. The company is incorporated in Delaware and headquartered at 300 Rouse Blvd., Philadelphia, Pennsylvania 19112. Its common stock, par value $0.000041666 per share, is listed on The Nasdaq Stock Market, LLC under the symbol IOVA.

What Was Disclosed

Iovance Biotherapeutics filed an 8-K on October 29, 2026, reporting updated Phase 2 IOV-LUN-202 Cohort 1 and 2 results and a biomarker-enriched precision strategy for lifileucel in non-squamous metastatic non-small-cell lung cancer, with full details in the attached press release.